In conclusion, challenges remain for the diagnosis, prevention, and management of RBC Alloimmunization in SCD. Understanding the mechanisms and associated risk factors will aid in developing strategies to prevent and inhibit production of antibodies in transfused patients and to minimize its life threatening complications resulting from transfusions.
Red blood cell Alloimmunization in SCD patients During pregnancy the antibodies and antigens production levels are traced to be abnormal in women. Such changes can affect the health of the mother and as well the new born along with many complications during pregnancy. RBC Alloimmunization is also one such condition which occurs due to the formation of antibodies to red blood cell antigens in the recipient from previous blood transfusions or a pregnancy. Sometimes this condition is also traced when the body is not exposed to foreign RBC antigens earlier before the transfusions. The formation of antibodies in the human body differs extensively depending on the patient’s disease, history of transfusions, pregnancy and the rate of antigens production against the donors of different geographical locations. In order to trace the level of RBC Alloimmunization keeping the record of the antibody and antigen rates against the transfusions is important. Normally, the rate of red cell antibodies is estimated to be 20% or more in patients with transfusion dependent diseases like sickle cell anemia and thalassemia etc. Sickle-cell disease (SCD) is an autosomal recessive genetic blood disorder with over dominance, characterized by red blood cells that assume an abnormal, rigid, sickle shape. Sickling decreases the cells flexibility and results in a risk of various complications. The sickling occurs because of a mutation in the hemoglobin gene during a transfusion. However, Red blood cell transfusions have reduced despair and mortality for patients with sickle cell disease. Transfusions can anyhow lead to RBC Alloimmunization. Blood transfusion is an essential treatment for the patients with sickle cell disease (SCD). However, transfusions can lead to RBC Alloimmunization with serious complications for the patient. These antibodies produced in such conditions are often directed against antigens expressed on RBC’s of white persons, donors of western countries. However, finding such donors lacking those antigens can sometimes be difficult and identifying and characterizing the antibodies can be a time consuming job causing transfusion delays. The most serious consequence of RBC Alloimmunization in SCD patients is the risk of developing a delayed hemolytic transfusion reaction (DHTR), which can be life taking. In many cases, the patient's hemoglobin level falls below the pre transfusion level indicating that the patient own RBCs are lysed in addition to hemolysis of the transfused RBCs. This condition is known as hyperhemolysis. Additional transfusions may provoke the hemolysis and further worsen the degree of anemia in the patients. Not all patients develop all antibodies after exposure to transfused RBCs. This fact pertains not only to patients with SCD but also to other transfused recipients. RBC Alloimmunization cannot be entirely prevented except by transfusions from an identical twin or by autologous transfusions. Preventing RBC antibody formation is also not practical for most patients and, for man yit causes no serious complications. But prevention of RBC Alloimmunization is important in women of child bearing age, and for some patients at risk of serious haemolytic transfusion reactions. It is currently unknown whether RBC Alloimmunization rates differ depending on the presence or absence of clinical complications of SCD. In conclusion, challenges remain for the diagnosis, prevention, and management of RBC Alloimmunization in SCD. Understanding the mechanisms and associated risk factors will aid in developing strategies to prevent and inhibit production of antibodies in transfused patients and to minimize its life threatening complications resulting from transfusions. Also, Immuno modulatory therapies, such as the use of immune cell depleting agents, costimulatory blockade, and cytokine blockade, may be effective in suppressing RBC Alloimmunization in patients. Tracing the conditions and taking timely precautions can help to recover from such complications during the pregnancy.
Pages to are hidden for
"Red blood cell Alloimmunization in SCD patients"Please download to view full document